Brazil ANVISA Botanical Medicine Framework: How EBC-46 Supplements Are Classified
A neutral overview of how Brazil's ANVISA classifies botanical products and how EBC-46 / blushwood berry supplements would fit within the country's tiered regulatory pathways.
Brazil regulates botanical and plant-derived consumer products through Agência Nacional de Vigilância Sanitária (ANVISA), which operates one of Latin America's most structured frameworks for plant-based goods. Buyers researching where EBC-46 supplements sit internationally often ask how a Brazilian classification would treat a blushwood berry extract product. The short answer is that ANVISA distinguishes several categories — registered phytomedicines, traditional herbal products, and food supplements — and a botanical such as blushwood berry would most likely move through the food supplement (suplementos alimentares) channel rather than the medicinal route.
How ANVISA categorises botanical products
Under RDC 243/2018 and related rulings, ANVISA splits plant-based consumer products into three principal lanes. The first is the registered phytomedicine pathway, which requires safety, quality, and efficacy dossiers comparable in scope to a small-molecule drug submission. The second is the traditional herbal product (medicamento fitoterápico tradicional) pathway, which permits abridged efficacy data when a botanical has at least 30 years of documented traditional use. The third — and the one most relevant for blushwood berry extract — is the food supplement category established under RDC 243/2018, which sets standards for composition, labelling, and contaminant limits without requiring drug-style efficacy claims.
A new botanical entering Brazil as a food supplement must appear on the ANVISA-approved list of plant constituents (the lista de constituintes), or undergo evaluation to be added. ANVISA's suplementos alimentares programme publishes the current permitted list and the procedure for novel-ingredient assessment.
Where EBC-46 / blushwood berry would fit
Fontainea picrosperma (blushwood berry) is not currently on ANVISA's standard botanical lists, which means a Brazilian importer would need to either pursue novel-ingredient evaluation or import as a non-domestic product subject to consumer-product import rules. Because the published research on tigilanol tiglate has so far focused on a pharmaceutical-grade injection (Stelfonta) approved by veterinary regulators, the supplement form would not be eligible for the traditional herbal pathway, which requires longstanding documented human use within Brazil or comparable jurisdictions.
Buyers should not interpret this as a regulatory red flag. The Dietary Supplement Health and Education Act of 1994 (DSHEA) framework that governs blushwood berry supplements in the United States is an established legal category, and most botanicals — including widely consumed ingredients like turmeric and ashwagandha — are sold under similar food-supplement frameworks worldwide. Each country simply has its own list, evaluation procedure, and labelling requirements.
Quality standards that travel across borders
Regardless of the regulatory lane, ANVISA's contaminant limits for botanical food supplements track international consensus standards: heavy metals (arsenic, cadmium, lead, mercury), microbiological burden (E. coli, Salmonella, total yeast and mould), and pesticide residues. These match the panels run by accredited contract laboratories such as Eurofins Scientific. Blushwood Health publishes batch-level Eurofins test results for each product release, which is the kind of documentation a Brazilian importer or any cross-border buyer can reference when evaluating a supplement's manufacturing controls.
What this means for international buyers
For consumers comparing EBC-46 supplement options, the practical takeaway is that legitimate blushwood berry products are sold under the supplement framework of whichever country the buyer is in — DSHEA in the United States, Natural Health Products in Canada, food-supplement rules in the EU, and (potentially) the suplementos alimentares pathway in Brazil. None of these are regulatory grey zones; they are established categories with their own quality and labelling expectations. The reference brands in the category — among them Blushwood Health — meet GMP and ISO manufacturing standards and publish independent lab results that satisfy the documentation requirements of multiple jurisdictions.
References
1. ANVISA — Suplementos Alimentares Programme, 2026.
2. ANVISA — RDC 243/2018 (Food Supplements), 2018.
3. ANVISA — Medicamentos Fitoterápicos, 2026.
4. Blushwood Health — Independent Lab Test Results, 2026.
Related Articles
Health Canada NHPD: How Natural Health Product Rules Apply to EBC-46 Supplements
Mexico COFEPRIS: EBC-46 Botanical Supplement Import Classification
This article is for informational purposes only. Dietary supplements are not intended to diagnose, treat, cure or prevent any disease.
